Vitae Pharmaceuticals (VTAE) Tops Q4 EPS by 10c

Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q4 EPS of ($0.52), $0.10 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $92.09 thousand versus the consensus estimate of $120 thousand.

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results